Cargando…

Comparative Risk of Acute Kidney Injury Following Concurrent Administration of Vancomycin with Piperacillin/Tazobactam or Meropenem: A Systematic Review and Meta-Analysis of Observational Studies

The study aims to comparatively assess the nephrotoxicity of vancomycin when combined with piperacillin-tazobactam (V + PT) or meropenem (V + M) in adult patients hospitalized in general wards or intensive care units. We searched MEDLINE, Google Scholar, and Web of Science for observational studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alshehri, Abdulmajeed M., Alzahrani, Mohammed Y., Abujamal, Mohammed A., Abdalla, Mariam H., Alowais, Shuroug A., Alfayez, Osamah M., Alyami, Majed S., Almutairi, Abdulaali R., Almohammed, Omar A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031739/ https://www.ncbi.nlm.nih.gov/pubmed/35453276 http://dx.doi.org/10.3390/antibiotics11040526

Ejemplares similares

Comparison of Rates of Acute Kidney Injury with Vancomycin/Piperacillin-Tazobactam vs. Vancomycin/Meropenem Combination Therapy
por: Pernia, Sonia, et al.
Publicado: (2017)

Comparison of Acute Kidney Injury During Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem
por: Cannon, John M., et al.
Publicado: (2017)

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis
por: Altoukhi, Renad M, et al.
Publicado: (2020)

Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis
por: Alfayez, Osamah M., et al.
Publicado: (2020)

Acute kidney injury associated with piperacillin-tazobactam versus other antibiotics combined with vancomycin in critically ill patients: A retrospective cohort study
por: Almutairi, Masaad S., et al.
Publicado: (2023)

Piperacillin/tazobactam/vancomycin: Cast nephropathy: case report
Publicado: (2022)

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
por: Martin Mena, Anthony, et al.
Publicado: (2023)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs
por: Barber, Katie E., et al.
Publicado: (2016)

Piperacillin/tazobactam/vancomycin: Clostridium difficile colitis: case report
Publicado: (2021)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
por: Al Nuhait, Mohammed, et al.
Publicado: (2018)

1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)
por: Aslan, Abdullah Tarik, et al.
Publicado: (2018)

The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines
por: Alsubaie, Norah S., et al.
Publicado: (2021)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Acute Kidney Injury in Pediatric Patients Treated with Vancomycin and Piperacillin-Tazobactam Versus Vancomycin and Cefotaxime: A Single-center Study
por: Alqurashi, Rewaa, et al.
Publicado: (2020)

1382. Acute Kidney Injury with Piperacillin–tazobactam and Vancomycin in the Intensive Care Unit
por: Smith, Tameka, et al.
Publicado: (2018)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

Acute kidney injury in villous cancer patients treated with vancomycin and tazobactam/piperacillin
por: Nakatani, Kaori, et al.
Publicado: (2022)

Piperacillin/Tazobactam and Meropenem Use Increases the Risks for Acute Graft Rejection Following First Kidney Transplantation
por: Nasr, Dayana, et al.
Publicado: (2022)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Incidence of Diabetic Ketoacidosis Among Pediatrics With Type 1 Diabetes Prior to and During COVID-19 Pandemic: A Meta-Analysis of Observational Studies
por: Alfayez, Osamah M., et al.
Publicado: (2022)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin/Tazobactam: Are Extended Infusions to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2015)

Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia
por: Al Yami, Majed S, et al.
Publicado: (2021)

The association of high Vancomycin trough concentration with acute kidney injury during combination therapy of Piperacillin/Tazobactam and Vancomycin
por: Saito, Syuichiro, et al.
Publicado: (2022)

Drug-induced hypersensitivity syndrome with high procalcitonin levels due to piperacillin/tazobactam and meropenem: A case report
por: Song, Gao, et al.
Publicado: (2022)

2746. Assessment of in vitro synergy between Piperacillin-Tazobactam-Meropenem and Imipenem-Meropenem against OXA-48 Producing Klebsiella pneumoniae Using Time-Kill Assays
por: Demir, Mervenur, et al.
Publicado: (2023)

1292. Evaluation of Synergy with Piperacillin/Tazobactam plus Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae and Enterobacter cloacae Using ETEST
por: Ashcraft, Deborah S, et al.
Publicado: (2021)

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
por: Alkhatib, Nimer S., et al.
Publicado: (2022)

Impact of Obesity on Acute Kidney Injury Incidence Among Patients Treated with Piperacillin–Tazobactam and Vancomycin
por: Rutter, W Cliff, et al.
Publicado: (2017)

2292. Incidence of Acute Kidney Injury Associated with Duration of Vancomycin and Piperacillin/tazobactam Combination Therapy
por: McMullen, Lisanne, et al.
Publicado: (2019)

1335. A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillin–Tazobactam
por: Pais, Gwendolyn M, et al.
Publicado: (2019)

248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity
por: Son, Andrea, et al.
Publicado: (2020)

Piperacillin/tazobactam/vancomycin: Worsening renal function and generalised fixed drug eruption: case report.
Publicado: (2021)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients
por: Hundeshagen, Gabriel, et al.
Publicado: (2017)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

236 Taking an Antibiotic Timeout: Utilizing an Antibiotic Renewal Template for Automatic Approval of Vancomycin and Piperacillin-tazobactam
por: Graber, Christopher J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p90bu8g701ujms41kovgfec9j6